InterventionsHumans

Risk of New Cancer Diagnoses with GLP-1 Receptor Agonist, SGLT2 Inhibitor, DPP-4 Inhibitor, and Sulfonylurea Use in Type 2 Diabetes

ADA Scientific Sessions 2025 Abstract

The paper

Stacey M. Sklepinski, Jeph S. Herrin, Kavya Sindhu Swarna,

Joshua J. Neumiller, Rodolfo J. Galindo, Guillermo E. Umpierrez, Joseph S. Ross, Yihong Deng, Eric C. Polley, Mindy M. Mickelson,

Rozalina Grubina McCoy

Baltimore

ADA Scientific Sessions 2025 Abstract · 13 Jun 2025

Presented at ADA Scientific Sessions 2025 · Oral 308-OR

doi.org/10.2337/db25-308-or

SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Diabetes, Obesity & Metabolism · 8 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Drug Design, Development and Therapy · 5 Oct 2026